Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.

Expert Review of Anti-Infective Therapy

Volumn 16, Issue 5, 2018, Pages 367-368

  Plant, Aiden J ^a   Dunn, Alexander ^a   Porter, Robert J ^a  

^a ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; MEROPENEM; VANCOMYCIN; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM ISOLATION; CASE REPORT; CLINICAL ARTICLE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HUMAN; IN VIVO STUDY; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; PERITONITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; SEPTIC SHOCK; SPUTUM ANALYSIS; AGED; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTION;

AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TAZOBACTAM;

EID: 85047266028     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2018.1473079     Document Type: Letter

References (8)

1. Maraolo AE, Cascella M, Corcione S, et al. Management of multidrug-resistant pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev Anti Infect Ther. 2017;18:1–11.
2. Hu Y, Li L, Li W, et al. Combination antibiotic therapy versus monotherapy for pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents. 2013;42:492–496.
3. Peña C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis. 2013;57(2):208–216.
4. Cabot G, Bruchmann S, Mulet X, et al. Haussler S and Oliver A. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58(6):3091–3099.
5. ZERBAXA (ceftolozane/tazobactam) [package insert]. Lexington, MA: Cubist Pharmaceuticals, 2014.
6. ClinicalTrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). cited 2017 Jun02. Available at: https://clinicaltrials.gov/ct2/show/NCT02070757
7. Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56(1):56–66.
8. Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistance Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65(1):110–120.